All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for SANOFI, U.S. · Global life sciences company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 1

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 5

Budget/Appropriations

Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.

Medicare/Medicaid

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Medical/Disease Research/Clinical Labs

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.

Health Issues

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.

Taxation/Internal Revenue Code

Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues; implementation of PL 119-21.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.